Topical iontophoretic delivery: Progress to date and therapeutic potential

American Journal of Drug Delivery

Volumn 3, Issue 2, 2005, Pages 67-81

  Hirvonen, Jouni ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ATROPINE; CAFFEINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CORTISONE; DEXAMETHASONE; DICLOFENAC; EMLA; FENTANYL; FLUOROURACIL; GLYCOPYRRONIUM BROMIDE; IONTOCAINE; KETOROLAC; LIDOCAINE; LOCAL ANESTHETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGONUCLEOTIDE; OPIATE; PEPTIDE; PILOCARPINE; PIROXICAM; POLDINE METHYLSULFATE; PREDNISOLONE; THEOPHYLLINE; TRYPSINOGEN; UNINDEXED DRUG;

CANCER PAIN; CHRONIC PAIN; CIRCULATION; CONCENTRATION (PARAMETERS); CYSTIC FIBROSIS; DEVICE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TRANSPORT; ECZEMA; GERIATRIC CARE; HEADACHE; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; HYPERHIDROSIS; INFLAMMATION; IONTOPHORESIS; LOCAL ANESTHESIA; MEDICAL TECHNOLOGY; OSMOSIS; PAIN; PEDIATRICS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SAFETY; SKIN IRRITATION; SKIN SENSITIZATION; TRANSDERMAL PATCH;

EID: 22544469182     PISSN: 11759038     EISSN: None     Source Type: Journal    
DOI: 10.2165/00137696-200503020-00001     Document Type: Review

References (179)

1. Tyle P. Iontophoretic devices for drug delivery. Pharm Res 1986; 3: 318-26
2. Banga AK, Chien YW. Iontophoretic delivery of drugs: fundamentals, developments and biomedical applications. J Control Release 1988; 7: 1-24
3. Shaw JE, Chandrasekaran SK. Controlled topical delivery of drugs for systemic action. Drug Metab Rev 1978; 8: 223-33
4. Barry BW. Dermatological formulations: percutaneous absorption. New York: Marcel Dekker Inc., 1983
5. Guy RH, Hadgraft J. Transdermal drug delivery: the ground rules are emerging. Pharm Int 1985; 6: 112-6
6. Flynn GL. Mechanism of percutaneous absorption from physicochemical evidence. In: Bronaugh RL, Maibach HI, editors. Percutaneous absorption. 2nd ed. New York: Marcel Dekker Inc., 1989: 27-51
7. Barry BW. Mode of action of penetration enhancers in human skin. J Control Release 1987; 6: 85-97
8. Kydonieus AF. Fundamentals of transdermal drug delivery. In: Kydonieus AF, Berner B, editors. Transdermal delivery of drugs. Vol. I. Boca Raton (FL): CRC Press Inc., 1987: 3-16
9. Vermeer BJ. Skin irritation and sensitization. J Control Release 1991; 15: 261-6
10. Ledger PW. Skin biological issues in electrically enhanced transdermal delivery. Adv Drug Deliv Rev 1992; 9: 289-307
11. Ranade VV. Drug delivery systems: 6. Transdermal drug delivery. J Clin Pharmacol 1991; 31: 401-18
12. Singh P, Maibach HI. Iontophoresis in drug delivery: basic principles and applications. Therap Drug Carrier Syst 1994; 11: 161-213
13. Berner B, John VA. Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet 1994; 26: 121-34
14. Barry BW. Breaching the skin's barrier to drugs. Nat Biotechnol 2004; 22: 165-7
15. Karande P, Jain A, Mitragotri S. Discovery of transdermal penetration enhancers by high-throughput screening. Nat Biotechnol 2004; 22: 192-7
16. Bouwstra JA, Gooris GS, Bras W, et al. Small angle X-ray scattering: possibilities and limitations in characterization of vesicles. Chem Phys Lipids 1993; 64: 83-98
17. Foldvari M. Non-invasive administration of drugs through the skin: challenges in delivery system design. Pharm Sci Technol Today 2000; 3: 417-25
18. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev 2004; 5: 675-711
19. Cevc G, Gebauer D, Stieber J, et al. Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim Biophys Acta 1998; 1368: 201-15
20. Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science 1995; 269: 850-3
21. Prausnitz MR, Bose VG, Langer R, et al. Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci U S A 1993; 90: 10504-8
22. Dujardin N, Staess E, Kalia Y, et al. In vivo assessment of skin electroporation using square wave pulses. J Control Release 2002; 79: 219-27
23. Henry S, McAllister DV, Allen MG, et al. Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci 1998; 87: 922-5
24. Henry CM. Special delivery. C&EN 2000; 18: 49-65
25. Srinivasan V, Su M-H, Higuchi WI, et al. Iontophoresis of polypeptides: effect of ethanol pretreatment of human skin. J Pharm Sci 1990; 79: 588-91
26. Lankjaer L, Brange J, Grodsky GM, et al. Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pre-treatment. J Control Release 1998; 51: 47-56
27. Banga AK, Bose S, Ghosh TK. Iontophoresis and electroporation: comparisons and contrasts. Int J Pharm 1999; 179: 1-19
28. Kannikkanan K. Iontophoresis-based transdermal delivery systems. Biodrugs 2002; 16: 339-47
29. Kalia YN, Naik A, Garrison J, et al. Iontophoretic drug delivery. Adv Drug Deliv Rev 2004; 56: 619-58
30. Kennedy RM, Luhmann JD. Pharmacological management of pain and anxiety during emergency procedures in children. Paediatr Drugs 2001; 3: 337-54
31. Connolly M, de Berker D. Management of primary hyperhidrosis: a summary of the different treatment modalities. Am J Clin Dermatol 2003; 4: 681-97
32. Farrell PM, Mischler EH. Newborn screening for cystic fibrosis: the Cystic Fibrosis Neonatal Screening Study Group. Adv Pediatr 1992; 39: 35-70
33. Rao G, Guy RH, Glikfeld P, et al. Reverse iontophoresis: Noninvasive glucose monitoring in vivo in humans. Pharm Res 1995; 12: 1322-6
34. Tamada JA, Bohannon NJV, Potts RO. Measurement of blood glucose in diabetic subjects using non-invasive transdermal extraction. Nat Med 1995; 1: 1198-201
35. Kurnik RT, Berner B, Tamada J, et al. Design and simulation of a reverse iontophoretic glucose monitoring device. J Electrochem Soc 1998; 145: 4119-25
36. Tierney MJ, Tamada JA, Potts RO, et al. The GlucoWatch Biographer: a frequent automatic and non-invasive glucose monitor. Ann Med 2000; 32: 632-41
37. Guy RH. A sweeter life for diabetics? Nat Med 1995; 1: 1132-3
38. Kost J, Lapidot SA. Smart polymers for controlled drug delivery. In: Wise DL, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker, 2000: 65-87
39. Siegel RA, Ziaie B. Biosensing and drug delivery at the microscale. Adv Drug Deliv Rev 2004; 56: 121-2
40. Steil GM, Panteleon AE, Rebrin K. Closed-loop insulin delivery: the path to physiological glucose control. Adv Drug Deliv Rev 2004; 56: 125-44
41. Burnette RR. Iontophoresis. In: Hadgraft J, Guy RH, editors. Transdermal drug delivery: developmental issues and research initiatives. New York: Marcel Dekker, 1989: 247-91
42. Yoshida NH, Roberts MS. Structure-transport relationships in transdermal iontophoresis. Adv Drug Deliv Rev 1992; 9: 239-64
43. Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res 1996; 13: 1765-9
44. Delgado-Charro MB, Guy RH. Iontophoresis: applications in drug delivery and noninvasive monitoring. In: Guy RH, Hadgraft J, editors. Transdermal drug delivery. 2nd rev. exp. ed. New York: Marcel Dekker, 2003: 199-225
45. Hirvonen J, Jaskari T. New approaches in transdermal drug delivery. Eur Pharm Rev 2001; 2: 68-70
46. Phipps JB, Gyory JR. Transdermal ion migration. Adv Drug Deliv Rev 1992; 9: 137-76
47. Pikal M. Transport mechanisms in iontophoresis: I. A theoretical model for the effect of electroosmotic flow on flux enhancement in transdermal iontophoresis. Pharm Res 1990; 7: 118-26
48. Marro D, Guy RH, Delgado-Charro MB. Characterization of the iontophoretic permselectivity properties of human and pig skin. J Control Release 2001; 70: 213-7
49. Kasting GB. Theoretical models for iontophoretic delivery. Adv Drug Deliv Rev 1992; 9: 177-200
50. Burnette RR, Ongpipattanakul B. Characterization of the permselective properties of excised human skin during iontophoresis. J Pharm Sci 1987; 76: 765-73
51. Burnette RR, Ongpipattanakul B. Characterization of the pore transport properties and tissue alteration of excised human skin during iontophoresis. J Pharm Sci 1988; 77: 132-7
52. Pikal MJ, Shah S. Transport mechanisms in iontophoresis: II. Electroosmotic flow and transference number measurements for hairless mouse skin. Pharm Res 1990; 7: 213-21
53. Pikal MJ, Shah S. Transport mechanisms in iontophoresis: III. An experimental study of the contributions of electroosmotic flow and permeability change in transport of low and high molecular weight solutes. Pharm Res 1990; 7: 222-9
54. Sims SM, Higuchi WI, Srinivasan V. Skin alteration and convective solvent flow effects during iontophoresis: I. Neutral solute transport across human skin. Int J Pharm 1991; 69: 109-21
55. Cullander C, Guy RH. Sites of iontophoretic current flow into the skin: identification and characterization with the vibrating probe electrode. J Invest Dermatol 1991; 97: 55-64
56. Turner N, Ferry L, Price M, et al. Iontophoresis of poly-l-lysines: the role of molecular weight. Pharm Res 1997; 14: 1322-31
57. Cullander C. What are the pathways of iontophoretic current flow through mammalian skin? Adv Drug Deliv Rev 1992; 9: 119-36
58. Scott ER, Laplaiza AI, White HS, et al. Transport of ionic species in skin: contribution of pores to the overall skin conductance. Pharm Res 1993; 10: 1699-709
59. Pikal MJ. The role of electroosmotic flow in transdermal iontophoresis. Adv Drug Deliv Rev 1992; 9: 201-37
60. Delgado-Charro BM, Guy RH. Characterization of convective solvent flow during iontophoresis. Pharm Res 1994; 11: 929-35
61. Hirvonen J, Kalia YN, Guy RH. Transdermal delivery of peptides by iontophoresis. Nat Biotech 1996; 14: 1710-3
62. Hirvonen J, Guy RH. Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances. Pharm Res 1997; 14: 1258-63
63. Santi P, Guy RH. Reverse iontophoresis: parameters determining electroosmotic flow: I. pH and ionic strength. J Control Release 1996; 38: 159-65
64. Santi P, Guy RH. Reverse iontophoresis: parameters determining electroosmotic flow: II. Electrode chamber formulation. J Control Release 1996; 42: 29-36
65. Sloan JB, Soltani K. Iontophoresis in dermatology. J Am Acad Dematol 1986; 15: 671-84
66. Anderson LL, Welch ML, Grabski WJ. Allergic contact dermatitis and reactivation phenomenon from iontophoresis of 5-fluorouracil. J Am Acad Dermatol 1997; 36: 478-9
67. Foti C, Cassano N, Conserva A, et al. Allergic contact dermatitis due to diclofenac applied with iontophoresis. Clin Exp Dermatol 2004; 29: 91-7
68. Gwynne P. Companies developing more uses for iontophoresis. Scientist 1997; 11: 1-4
69. Scott ER, Phipps JB, Gyory JR, et al. Electrotransport systems for transdermal drug delivery: a practical implementation of iontophoresis. In: Wise DL, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker, 2000: 617-59
70. Conaghey OM, Corish J, Corrigan OI. Iontophoretically assisted in vitro membrane transport of nicotine from a hydrogel containing ion exchange resins. Int J Pharm 1998; 170: 225-37
71. Åkerman S, Viinikka P, Svarfvar B, et al. Transport of drugs across porous ion exchange membranes. J Control Release 1998; 50: 153-66
72. Jaskari T, Vuorio M, Manzanares JA, et al. Controlled transdermal iontophoresis by ion-exchange fiber. J Control Release 2000; 67: 179-90
73. Anand V, Kandarapu R, Garg S. Ion-exchange resins: carrying drug delivery forward. Drug Discov Today 2001; 6: 905-14
74. Kankkunen T, Huupponen I, Lahtinen K, et al. Improved stability and release control of levodopa and metaraminol using ion-exchange fibers and transdermal iontophoresis. Eur J Pharm Sci 2002; 16: 273-80
75. Jaskari T, Vuorio M, Manzanares JA, et al. Ion-exchange fibers and drugs: an equilibrium study. J Control Release 2001; 70: 219-29
76. Vuorio M, Manzanares JA, Murtomäki L, et al. Ion-exchange fibres and drugs: a transient study. J Control Release 2003; 91: 439-48
77. Hänninen K, Kaukonen AM, Kankkunen T, et al. Rate and extent of ion-exchange process: the effect of physico-chemical characteristics of salicylate anions. J Control Release 2003; 91: 449-63
78. Helfferich F. Ion exchange. New York: Dover Publications Inc., 1995
79. Kankkunen T, Sulkava R, Vuorio M, et al. Transdermal iontophoresis of tacrine. Pharm Res 2002; 19: 705-8
80. Vuorio M, Murtomäki L, Hirvonen J, et al. Ion-exchange fibers and drugs: a novel device for the screening of iontophoretic systems. J Control Release 2004; 97: 485-92
81. Lyklema J. Fundamentals of colloid and interface science. Vol. 1. London: Academic, 1991
82. Laksminarayanaiah N. Equations of membrane biophysics. Orlando (FL): Academic, 1984
83. Costello CT, Jeske AH. Iontophoresis: applications in transdermal medication delivery. Phys Ther 1995; 75: 554-63
84. Li LC, Scudds RA. Iontophoresis: an overview of the mechanisms and clinical application. Arthritis Care Res 1995; 8: 51-61
85. Riedl CR, Plas E, Engelhardt P, et al. Iontophoresis for treatment of Peyronie's disease. J Urol 2000; 163: 95-9
86. Tiwari SB, Kumar BC, Udupa N, et al. Topical methotrexate delivered by iontophoresis in the treatment of recalcitrant psoriasis: case report. Int J Dermatol 2003; 42: 157-9
87. Voigt M, Kralinger M, Kieselbach G, et al. Ocular aspirin distribution: a comparison of intravenous, topical, and coulomb-controlled iontophoresis administration. Invest Ophthalmol Vis Sci 2002; 43: 3299-306
88. Hamilton JG. Needle phobia: a neglected diagnosis? J Fam Pract 1995; 41: 169-75
89. Kennedy RM, Luhmann JD. Pharmacological management of pain and anxiety during emergency procedures in children. Paediatr Drugs 2001; 3: 337-54
90. Zempsky WT, Anand KJS, Sullivan KM, et al. Lidocaine iontophoresis for topical anesthesia before intravenous line placement in children. J Pediatr 1998; 132: 1061-3
91. Zempsky WT, Parkinson TM. Lidocaine iontophoresis for topical anesthesia before dermatologic procedures in children: a randomized controlled trial. Pediatr Dermatol 2003; 20: 364-8
92. Ashburn MA, Gauthier M, Love G, et al. Iontophoretic administration of 2% lidocaine HCl and 1:100 000 epinephrine in humans. Clin J Pain 1997; 13: 22-6
93. Kim MK, Kini NM, Troshynski TJ, et al. A randomized clinical trial of dermal anesthesia by iontophoresis for peripheral intravenous catheter placement in children. Ann Emerg Med 1999; 33: 395-9
94. Gupta SK, Bernstein KJ, Noorduin H, et al. Fentanyl delivery from an electrotransport system: delivery is a function of total current, not duration of current. J Clin Pharmacol 1998; 38: 951-8
95. Gupta SK, Southam M, Sathyan G, et al. Effect of current density on pharmacokinetics following continuous or intermittent input from a fentanyl electrotransport system. J Pharm Sci 1998; 87: 979-81
96. Gupta SK, Sathyan G, Phipps B, et al. Reproducible fentanyl doses delivered intermittently at different time intervals from an electrotransport system. J Pharm Sci 1999; 88: 835-41
97. Lacy C, Armstrong L, Ingram N, et al. Drug information handbook. 7th ed. Cleveland (OH): LexiComp Inc., 1995
98. Wieder DL. Treatment of traumatic myositis ossificans with acetic acid iontophoresis. Phys Ther 1992; 72: 133-7
99. Petelenz TJ, Buttke JA, Bonds LB, et al. Iontophoresis of dexametasone: laboratory studies. J Control Release 1992; 20: 55-66
100. Gudemann SD, Eisele SA, Heidt RS, et al. Treatment of plantar fasciitis by iontophoresis of 0.4% dexamethasone: a randomized, double blind, placebo controlled study. Am J Sports Med 1997; 25: 312-6
101. Osterman AL, Whitman M, Porta LD. Nonoperative carpal tunnel syndrome treatment. Hand Clin 2002; 18: 279-89
102. James MP, Graham RM, English J. Percutaneous iontophoresis of prednisolone: a pharmacokinetic study. Clin Exp Dermatol 1986; 11: 54-61
103. Aetna. Clinical policy bulletin #0229. Subject: iontophoresis [online]. Available from URL: http://www.aetna.com/cpb/data/CPBA0229.html [Accessed 2005 Apr 5]
104. Banta CA. A prospective, nonrandomized study of iontophoresis, wrist splinting, and anti-inflammatory medication in the treatment of early-mild carpal tunnel syndrome. J Occup Med 1994; 36: 166-8
105. Connolly M, de Berker D. Management of primary hyperhidrosis: a summary of the different treatment modalities. Am J Clin Dermatol 2003; 4: 681-97
106. Sloan JB, Soltani K. Iontophoresis in dermatology. J Am Acad Dermatol 1986; 15: 671-84
107. Reinauer SA, Neusser G, Schauf G, et al. Iontophoresis with alternating current and direct current offset (AC DC iontophoresis): a new approach for the treatment of hyperhidrosis. Br J Dermatol 1993; 129: 166-9
108. Elgart ML, Fuchs G. Tapwater iontophoresis in the treatment of hyperhidrosis. Int J Dermatol 1987; 26 (3): 194-7
109. Abell E, Morgan K. The treatment of idiopathic hyperhidrosis by glycopyrronium bromide and tap water iontophoresis. Br J Dermatol 1974; 91: 87-91
110. Akins DL, Meisenheimer JL, Dobson RL. Efficacy of the Drionic unit in the treatment of hyperhidrosis. J Am Acad Dermatol 1987; 26: 828-32
111. Hölzle E, Alberti N. Long-term efficacy and side effects of tap water iontophoresis of palmoplantar hyperhidrosis: the usefulness of home therapy. Dermatologica 1987; 175: 126-35
112. Shen J, Lin GS, Li WM. A new strategy of iontophoresis for hyperhidrosis. J Am Acad Dermatol 1990; 22: 239-41
113. Boat TF. Cystic fibrosis. In: Behrman RE, editor. Nelson textbook of pediatrics. 16th ed. Philadelphia, PA: WB Saunders, 2000
114. Thompson MM, Marshik P. Cystic fibrosis. In: Rakel RE, editor. Conn's current therapy. 52nd ed. Philadelphia, PA: WB Saunders, 2000
115. Ranieri E, Lewis BD, Gerace RL, et al. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience. BMJ 1994; 308: 1469-72
116. Mischler EH, Wilfond BS, Fost N, et al. Cystic fibrosis newborn screening: impact on reproductive behaviour and implications for genetic counseling. Pediatrics 1998; 102: 44-52
117. Gibson LE, Cooke RE. A test for the concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959; 23: 545-9
118. Rattenbury JM, Worthy E. Is the sweat test safe? Some instances of burns received during pilocarpine iontophoresis. Ann Clin Biochem 1996; 33: 456-8
119. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-1036
120. Tierney MJ, Jayalakshmi Y, Parris NA, et al. Design of a biosensor for continual, transdermal glucose monitoring. Clin Chem 1999; 45: 1681-3
121. Potts RO. Glucose monitoring by reverse iontophoresis. Diabetes Metab Res 2001; 17 Suppl.: s1-6
122. Tamada JA, Garg S, Jovanovic L, et al. Nonivasive glucose monitoring: comprehensive clinical results. JAMA 1999; 282: 1839-44
123. Langer R. Transdermal drug delivery: past progress, current status, and future prospects. Adv Drug Deliv Rev 2004; 56: 557-8
124. Merino V, Lopez A, Hochstrasser D, et al. Noninvasive sampling of phenylalanine by reverse iontophoresis. J Control Release 1999; 61: 65-9
125. Sekkat N, Naik A, Kalia YN, et al. Reverse iontophoretic monitoring in premature neonates: feasibility and potential. J Control Release 2002; 81: 83-9
126. Degim IT, Ilbasmis S, Dundaroz R, et al. Reverse iontophoresis: a non-invasive technique for measuring blood urea level. Pediatr Nephrol 2003; 18: 1032-7
127. Kalia YN, Nonato LB, Guy RH. The effect of iontophoresis on skin barrier integrity: non-invasive evaluation by impedance spectroscopy and tranry sepidermal water loss. Pharm Res 1996; 13: 957-60
128. Kalia YN, Nonato LB, Lund CH, et al. Development of skin barrier function in premature infants. J Invest Dermatol 1998; 111: 320-6
129. Nonato LB, Kalia YN, Naik A, et al. The development of skin barrier function in the neonate. Basic Clin Dermatol 2002; 21: 43-75
130. Warwick WJ, Huang NN, Waring WW, et al. Evaluation of a cystic fibrosis screening system incorporating a miniature sweat stimulator and disposable chloride sensor. Clin Chem 1986; 32: 850-3
131. Yeung WH, Palmer J, Schidlow D, et al. Evaluation of a paper-patch test for sweat chloride determination. Clin Pediatr 1984; 23: 603-7
132. Barrett DA, Rutter N. Transdermal delivery and the premature neonate. Crit Rev Ther Drug Carrier Syst 1994; 11: 1-30
133. Koren G. Therapeutic drug monitoring principles in the neonate. Clin Chem 1997; 43: 222-7
134. Merino V, Kalia YN, Guy RH. Transdermal therapy and diagnosis by iontophoresis. Trends Biotechnol 1997; 15: 288-90
135. Saraheimo M. Treatment of type 1 diabetes [in Finnish with an English summary]. Dosis 2003; 19: 208-12
136. van der Geest R, Danhof M, Bodde HE. Iontophoretic delivery of apomorphine. I: in vitro optimization and validation. Pharm Res 1997; 14: 1798-803
137. van der Geest R, van Laar T, Gubbens-Stibbe JM, et al. Iontophoretic delivery of apomorphine. II: an in vivo study in patients with Parkinson's disease. Pharm Res 1997; 14: 1804-10
138. Li GL, Danhof M, Frederik PM, et al. Pretreatment with a water-based surfactant formulation affects transdermal iontophoretic delivery of R-apomorphine in vitro. Pharm Res 2003; 20: 653-9
139. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 1994; 4: 510-40
140. Sathyan G, Ritschel WA, Hussain AS. Transdermal delivery of tacrine: I. Identification of a suitable delivery vehicle. Int J Pharm 1995; 14: 75-83
141. Ashburn MA, Streisand J, Zhang J, et al. The iontophoresis of fentanyl citrate in humans. Anaesthesiology 1995; 82: 1146-53
142. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999; 318: 633-8
143. Dooley M, Lamb HM. Donepezil: a review of its use in Alzheimer's disease. Drugs Aging 2000; 16: 199-226
144. Amsden BG, Goosen MFA. Transdermal delivery of peptide and protein drugs: an overview. AIChE Journal 1995; 41: 1972-97
145. Green PG. Iontophoretic delivery of peptide drugs. J Control Release 1996; 41: 33-48
146. Liu J-C, Sun Y, Siddiqui O, et al. Blood glucose control in diabetic rats by transdermal iontophoretic delivery of insulin. Int J Pharm 1988; 44: 197-204
147. Haga M, Akatani M, Kikuchi J, et al. Transdermal iontophoretic delivery of insulin using a photoetched microdevice. J Control Release 1997; 43: 139-49
148. Kanikkannan N, Singh J, Ramarao P. Transdermal iontophoretic delivery of bovine insulin and monomeric human insulin analogue. J Control Release 1999; 59: 99-105
149. Heit MC, Williams PL, Jayes FL, et al. Transdermal iontophoretic peptide delivery: in vitro and in vivo studies with luteinizing hormone releasing hormone. J Pharm Sci 1993; 82: 240-3
150. Hoogstraate AJ, Srinivasan V, Simms SM, et al. Iontophoretic enhancement of peptides: behavior of leuprolide versus model permeants. J Control Release 1994; 31: 41-7
151. Chen L-LH, Chien YW. Transdermal iontophoretic permeation of luteinizing hormone releasing hormone: characterization of electric parameters. J Control Release 1996; 40: 187-98
152. Kochhar C, Imanidis G. In vitro transdermal iontophoretic delivery of Leuprolide: mechanisms under constant voltage application. J Pharm Sci 2003; 92: 84-96
153. Raiman J, Naakka M, Huikko K, et al. Delivery and stability of LHRH and Nafarelin in human skin: the effect of constant/pulsed iontophoresis, Eur J Pharm Sci 2004; 21: 371-377
154. Thysman S, Hanchard C, Preat V. Human calcitonin delivery in rats by iontophoresis. J Pharm Pharmacol 1994; 46: 725-30
155. Santi P, Colombo P, Bettini R, et al. Drug reservoir composition and transport of salmon calcitonin in transdermal iontophoresis. Pharm Res 1997; 14: 63-6
156. Chang SL, Hofmann GA, Zhang L, et al. Transdermal iontophoretic delivery of salmon calcitonin. Int J Pharm 2000; 200: 107-13
157. Suzuki Y, Iga K, Yanai S, et al. Iontophoretic pulsatile transdermal delivery of human parathyroid hormone (1-34). J Pharm Pharmacol 2001; 53: 1227-34
158. Suzuki Y, Nagase Y, Iga K, et al. Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH(1-34). J Pharm Sci 2002; 91: 350-61
159. Banga AK, Chien YW. Hydrogel-based iontotherapeutic delivery devices for transdermal delivery of peptide/protein drugs. Pharm Res 1993; 10: 697-702
160. Banga AK, Katakam M, Mitra R. Transdermal iontophoretic delivery and degradation of vasopressin across human cadaver skin. Int J Pharm 1995; 116: 211-216
161. Kumar S, Char H, Patel S, et al. In vivo transdermal iontophoretic delivery of growth hormone releasing factor GRF (1-44) in hairless guinea pigs. J Control Release 1992; 18: 213-20
162. Guy RH, Kalia YN, Delgado-Charro MB, et al. Iontophoresis: electrorepulsion and electroosmosis. J Control Release 2000; 64: 129-32
163. Marro D, Kalia YN, Delgado-Charro MB, et al. Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm Res 2001; 18: 1701-8
164. Knoblauch P, Moll F. In vitro pulsatile and continuous transdermal delivery of buserelin by iontophoresis. J Control Release 1993; 26: 203-12
165. Chen L-LH, Chien YW. Transdermal iontophoretic permeation of luteinizing hormone releasing hormone: characterization of electric parameters. J Control Release 1996; 40: 187-98
166. Vlassov VV, Nechaeva MV, Karamyshev VN, et al. Iontophoretic delivery of oligonucleotide derivatives into mouse tumor. Antisense Res Dev 1994; 4: 291-3
167. Zakzevski CA, Amory DW, Jasaitis DK, et al. Iontophoretically enhanced transdermal delivery of an ACE inhibitor in induced hypertensive rabbits: preliminary report. Cardiovasc Drugs Ther 1992; 6: 589-95
168. Oldenburg KR, Vo KT, Smith GA, et al. Iontophoretic delivery of oligonucleotides across full thickness hairless mouse skin. J Pharm Sci 1995; 84: 915-21
169. Brand RM, Iversen PL. Iontophoretic delivery of a telomeric oligonucleotide. Pharm Res 1996; 13: 851-4
170. Zewert TE, Pliquett UF, Langer R, et al. Transdermal transport of DNA antisense oligonucleotides by electroporation. Biochem Biophys Res Commun 1995; 212: 286-92
171. Regnier V, Preat V. Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm Res 1998; 15: 1596-602
172. Regnier V, Le Doan T, Preat V. Parameters controlling topical delivery of oligonucleotides by electroporation. J Drug Target 1998; 5: 275-89
173. Brand RM, Iversen PL. Transdermal delivery of antisense compounds. Adv Drug Deliv Rev 2000; 44: 51-7
174. Bishop MR, Iversen PL, Bayever E, et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 1996; 14: 1320-6
175. Brand RM, Wahl A, Iversen P. Effects of size and sequence on the iontophoretic delivery of oligonucleotides. J Pharm Sci 1998; 87: 49-52
176. Brand RM, Hannah TL, Norris J, et al. Transdermal delivery of antisense oligonucleotides can induce changes in gene expression in vivo. Antisense Nucleic Acid Drug Dev 2001; 11: 1-6
177. Wigens M, van Hooijdonk CA, de Jongh GJ, et al. Flow cytometric and microscopic characterization of the uptake and distribution of phosphorothioate oligonucleotides in human keratinocytes. Arch Dermatol 1998; 290: 119-25
178. Regnier V, Preat V. Localisation of an FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm Res 1998; 15: 1596-602
179. Dujardin N, Van der Smissen P, Preat V. Topical gene transfer into rat skin using electroporation. Pharm Res 2001; 18: 61-6